Immunology-Immunotherapy

(P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP

(P 98) TUMOR IMMUNE PROFILING AND IDENTIFICATION OF IMMUNOTHERAPEUTIC TARGETS IN DEDIFFERENTIATED LIPOSARCOMA

(P 99) M2 MACROPHAGE INFILTRATION IS ASSOCIATED WITH EARLY DISEASE RECURRENCE FOLLOWING CURATIVE INTENT SURGICAL RESECTION IN SOFT-TISSUE SARCOMAS

(P 100) HISTOLOGY SPECIFIC INTRATUMORAL B-CELL BIOLOGY IN ALVEOLAR SOFT-PART SARCOMAS (ASPS) IN RESPONSE TO DURVALUMAB-TREMELIMUMAB (D-T)

(P 101) EPIGENETIC MODULATION OF NK CELLS IMPROVES TUMOR TRAFFICKING AND ENHANCES THERAPEUTIC EFFICACY AGAINST OSTEOSARCOMA

(P 102) INTERLEUKIN-6 IN RELATION TO TUMOR BEHAVIOR AND EARLY RECURRENCE IN PRIMARY LOCALIZED SOFT TISSUE SARCOMA

(P 103) LASTING COMPLETE RESPONSE TO PEMBROLIZUMAB IN MISMATCH REPAIR DEFICIENT CARDIAC SARCOMA: A GENOMIC CHARACTERIZATION

(P 105) STING THERAPY INDUCES IMMUNOGENIC ANTI-TUMOR RESPONSES THAT ARE INDEPENDENT OF TUMOR STING EXPRESSION IN THE KP MODEL OF SOFT TISSUE SARCOMA

(P 106) CHARACTERIZATION OF AN IMMUNE COMPETENT, MURINE MODEL OF SOFT TISSUE SARCOMA

(P 107) TRABECTEDIN AUGMENTS ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY EFFICACY IN PRECLINCAL BONE SARCOMA MODELS THROUGH ENHANCED IMMUNE-MEDIATED MECHANISMS

(P 108) EFFECT OF TUMOUR-TARGETED HYPERTHERMIA AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF EMBRYONAL RHABDOMYOSARCOMA

(P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA

(P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS

(P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS

(P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA

(P 113) IMMUNOSARC II: A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF DOXORUBICIN AND DACARBAZINE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED LEIOMYOSARCOMA

(P 114) PRIMARY ANALYSIS OF EFFICACY AND SAFETY OF LETETRESGENE AUTOLEUCEL (LETE-CEL) AS FIRST-LINE TREATMENT FOR UNRESECTABLE OR METASTATIC SYNOVIAL SARCOMA (SS); SUBSTUDY 1 OF IGNYTE-ESO

(P 115) EFFICACY AND CORREALTIVE ANALYSIS OF USING NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS

(P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]

(P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)

(P 118) TIM-3 QUALIFIES AS A POTENTIAL IMMUNOTHERAPEUTIC TARGET IN SPECIFIC SUBSETS OF PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS (HR-STS)

(P 119) EX VIVO EXPANDED TUMOR INFILTRATING LYMPHOCYTES FOR SARCOMA TREATMENT

(P 120) THE FEASIBILITY OF CD47-BASED IMMUNOTHERAPY FOR OSTEOSARCOMA

(P 121) IMPROVING THE EFFICACY OF GD2 CHIMERIC ANTIGEN RECEPTOR T-CELLS USING HISTONE DEACETYLASE INHIBITORS

(P 122) TARGETING CD70 USING CAR NK CELLS TO ENHANCE NK CELLS CYTOLYTIC EFFECT AGAINST OSTEOSARCOMA

(P 123) DEDIFFERENTIATED LIPOSARCOMAS TREATED WITH IMMUNE CHECKPOINT BLOCKADE: THE MD ANDERSON EXPERIENCE

(P 124) UNLOCKING THE POTENTIAL OF MEASLES VIRUS ONCOLYTIC IMMUNOTHERAPY FOR SARCOMA: BIOMARKER DISCOVERY AND THERAPEUTIC VACCINE DEVELOPMENT

(P 125) MYELOMODULATORY TREATMENTS AUGMENT THE THERAPEUTIC BENEFIT OF ONCOLYTIC VIRUS IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS BY MODULATING THE TUMOR MICROENVIRONMENT